Medesis Pharma S.A. Logo

Medesis Pharma S.A.

Develops therapies for CNS disorders and radiation exposure via a drug delivery platform.

ALMDP | PA

Overview

Corporate Details

ISIN(s):
FR0010844464
LEI:
969500C15M96P00UR648
Country:
France
Address:
AVENUE DU GOLF, 34670 BAILLARGUES
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Medesis Pharma S.A. is a clinical-stage biopharmaceutical company that develops therapies for diseases with high unmet medical needs. The company's core focus is its proprietary AONYS® drug delivery platform, an innovative micro-emulsion technology. Designed for buccal (oral cavity) administration, AONYS® facilitates the intracellular delivery of diverse therapeutic molecules, such as interfering RNAs, metal ions, and peptides. A key differentiator of the platform is its ability to transport active ingredients across the blood-brain barrier, enabling new treatments for central nervous system disorders. The technology is engineered to be invisible to the immune system, allowing for protected transport. Medesis Pharma's development pipeline includes treatments for populations exposed to nuclear radiation.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-20 12:00
Legal Proceedings Report
MEDESIS PHARMA : OUVERTURE D'UNE PROCÉDURE DE LIQUIDATION JUDICIAIRE
French 184.2 KB
2024-11-20 17:45
Earnings Release
MEDESIS PHARMA A FINALISÉ L’ÉTUDE CLINIQUE POUR LE TRAITEMENT DE LA MALADIE D’A…
French 685.0 KB
2024-11-20 17:45
Regulatory News Service
MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'…
English 614.2 KB
2024-11-14 18:00
Legal Proceedings Report
MEDESIS PHARMA : CONVERSION DE LA PROCÉDURE DE SAUVEGARDE EN REDRESSEMENT JUDIC…
French 314.0 KB
2024-11-12 18:00
Quarterly Report
MEDESIS PHARMA : Rapport Financier Semestriel 2024
French 2.5 MB
2024-11-12 18:00
Earnings Release
MEDESIS PHARMA : Activités & résultats du 1er semestre 2024
French 1.1 MB
2024-10-08 08:00
Report Publication Announcement
Participation de MEDESIS PHARMA au Congrès mondial pour les études cliniques s…
French 487.6 KB
2024-10-08 08:00
Earnings Release
MEDESIS PHARMA to participate to the World Congress for Clinical Trials in Alz…
English 461.5 KB
2024-09-20 08:00
Earnings Release
MEDESIS PHARMA : Résultats encourageants de la première phase de l’essai cliniq…
French 236.8 KB
2024-09-04 17:45
Pre-Annual General Meeting Information
MEDESIS PHARMA : MISE À DISPOSITION DES DOCUMENTS PRÉPARATOIRES À L’ASSEMBLÉE G…
French 274.7 KB
2024-07-15 08:00
Earnings Release
MEDESIS PHARMA : ACTIVITÉS & RÉSULTATS ANNUELS 2023
French 828.9 KB
2024-07-15 08:00
Annual Report
MEDESIS PHARMA: 2023 FULL-YEAR BUSINESS AND EARNINGS
English 737.2 KB
2024-06-03 18:00
Regulatory News Service
MEDESIS PHARMA : Obtention d’un financement pour poursuivre l'analyse des résul…
French 498.8 KB
2024-03-19 18:01
Share Issue/Capital Change
Termination of the agreement between NICE and GREEN S.A. and Medesis Pharma
English 264.7 KB
2024-03-19 18:01
Capital/Financing Update
Medesis Pharma : Résiliation du contrat avec la société NICE & GREEN S.A.
French 302.0 KB

Automate Your Workflow. Get a real-time feed of all Medesis Pharma S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Medesis Pharma S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Medesis Pharma S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-05-16 N/A Other Sell 1,000 1,170.00 EUR
2024-01-18 N/A Other Sell 800 669.60 EUR
2023-07-21 N/A Other Sell 1,000 1,400.00 EUR
2023-07-04 N/A Other Sell 5,000 7,100.00 EUR
2023-05-23 N/A Other Sell 3,140 6,908.00 EUR

Peer Companies

Company Country Ticker View
Biotech R&D using a miniature pig model, offering CRO services and biomaterials to pharma.
South Korea 149300
Arterra Bioscience Logo
Develops natural active ingredients via biotechnology for cosmetic, pharma, and food sectors.
Italy ABS
ASUA Inc. Logo
Consulting and solutions provider enhancing logistics safety and efficiency with IoT and telecom.
Japan 246A
Licenses patented material IP (MST®) to create higher-performance, lower-power semiconductors.
United States of America ATOM
Atrae, Inc. Logo
Develops People Tech solutions for HR, including big data job sites and organizational analytics.
Japan 6194
Developing uranium and battery minerals for the nuclear energy and energy storage markets.
Australia N/A
BayCurrent, Inc. Logo
Comprehensive consulting on strategy, AI, and digital transformation for corporations and government.
Japan 6532
BenevolentAI Logo
An AI-powered drug discovery platform accelerating R&D for scientists and pharmaceutical partners.
United Kingdom BAI
BerGenBio Logo
Develops first-in-class AXL kinase inhibitors for cancer and severe respiratory infections.
Norway BGBIO
Bergman & Beving Logo
Acquires and develops niche companies with solutions for the industrial and construction sectors.
Sweden BERG

Talk to a Data Expert

Have a question? We'll get back to you promptly.